For the first time, researchers at Penn’s Abramson Cancer Center have found that a mutation in the ATRX may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas that become malignant. These rare neuroendocrine tumors are typically benign, but when they go rogue, they become very aggressive.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.